Fig. 1From: Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysisConceptual model structure. BPH, benign prostate hyperplasia; 5-ARI, 5-α-reductase inhibitors; FT Fexapotide triflutate, AUR Acute urinary retention, TURP Transurethral resection of the prostate, HoLEP Holmium laser enucleation of the prostate, PVP Photoselective vaporization of the prostateBack to article page